Central Nervous System Disorder Drugs Market

Central Nervous System Disorder Drugs Market: Outlook

The exposure of numerous central nervous system disorders such as schizophrenia and Alzheimer’s along with the prevalence of a sedentary lifestyle among a considerable chunk of the global populace may bring great growth opportunities for the central nervous system disorder drugs market during the assessment period of 2020-2030.

Based on type, the central nervous system disorder drugs market can be segmented into anesthetics, antiparkinson drugs, analgesics, and other CNS drugs. In the context of the distribution channels, the central nervous system disorder drugs market can be classified into retail pharmacies, hospital pharmacies, drug stores, and others.

This report on the central nervous system disorder drugs market offers expansive insights into the diverse growth factors related to geographical analysis, recent developments, and the competitive landscape. The report also provides an array of information to the stakeholder about the COVID-19 effect on the central nervous system disorder drugs market.

Central Nervous System Disorder Drugs Market: Competitive Assessment

The central nervous system disorder drugs market has numerous players in fray for developing drugs that can effectively heal the varied central nervous system disorders without any side effects. Speedy regulatory approvals from regulators like FDA are also necessary for accelerating growth. For instance, satralizumab, a home-administered drug for treating a rare central nervous system disorder was recently approved by the FDA.

Major players involved in the central nervous system disorder drugs market are Johnson & Johnson, Biogen Inc., Pfizer Inc., F.Hoffmann-La Roche Ltd., and Novartis AG.

Central Nervous System Disorder Drugs Market: Regional Perspective

North America may gain an upper hand in terms of regional growth during the forecast period of 2020-2030 on the back of a large prevalence of central nervous system disorders across the region. Asia Pacific may also garner substantial growth due to the  rising cases of Alzheimer’s and Parkinson’s disease.